Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease (SAN-HQ) to be used in the development and manufacturing of ReiThera’s novel vaccine candidate against COVID-19. The vaccine candidate, which is based on ReiThera’s …
Tromsø, Norway, 17. June 2020 – Biotec Pharmacon (OSE: BIOTEC) announces it has officially rebranded to ArcticZymes Technologies. As previously announced and decided by the Annual General Meeting, Biotec Pharmacon ASA has formally changed its name to ArcticZymes Technologies ASA. The new name is formally registered with Brønnøysundregistrene and will trade under the new ticker “AZT” over the next days. …
Tromsø, Norway, 28. May 2020 – Biotec Pharmacon (OSE: Biotec) announces its subsidiary, ArcticZymes AS, has been granted by Innovation Norway up to NOK 1.6 million for a project to commercialize additional enzyme components required by diagnostic developers. ArcticZymes Cod UNG enzyme offers diagnostic developers a superior enzyme-based solution for preventing false-positive results without affecting sensitivity in molecular diagnostic tests. …
Tromsø, Norway, 20th May 2020 – Biotec Pharmacon (OSE: Biotec) announces that its subsidiary, ArcticZymes AS, has been granted up to NOK 1.65 million by Innovation Norway for a project to increase the manufacturing scale of its SAN-HQ enzyme ArcticZymes’ Salt Active Nuclease High Quality (SAN-HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior …